Shares of MyoKardia Inc. (NASDAQ:MYOK) were up 7.6% during mid-day trading on Wednesday . The company traded as high as $22.29 and last traded at $22.21, with a volume of 62,787 shares. The stock had previously closed at $20.65.

A number of equities analysts have weighed in on the stock. Zacks Investment Research cut shares of MyoKardia from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. Credit Suisse Group AG restated a “buy” rating and set a $20.00 price objective (up from $16.00) on shares of MyoKardia in a research report on Tuesday, July 12th. BMO Capital Markets assumed coverage on shares of MyoKardia in a research report on Wednesday, July 20th. They set an “outperform” rating and a $28.00 price objective for the company. Cowen and Company restated a “buy” rating on shares of MyoKardia in a research report on Friday, May 13th. Finally, Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of MyoKardia in a research report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. MyoKardia has an average rating of “Buy” and an average target price of $23.50.

The firm’s market capitalization is $563.64 million. The company’s 50 day moving average price is $17.52 and its 200 day moving average price is $12.63.

MyoKardia (NASDAQ:MYOK) last announced its earnings results on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $3.55 million for the quarter, compared to analyst estimates of $3.55 million. The business’s revenue was up .0% compared to the same quarter last year. On average, equities analysts anticipate that MyoKardia Inc. will post ($1.50) EPS for the current fiscal year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.